REG - Scancell Hlds - Block Listing Six Monthly Return

Scancell HoldingsAnnouncement

17/10/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231017:nRSQ2945Qa&default-theme=true

RNS Number : 2945Q  Scancell Holdings Plc  17 October 2023

Scancell Holdings plc

("Scancell" or the "Company")

 

Block Listing Six Monthly Return

 

Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for
the treatment of cancer and infectious disease, today makes the following
notification pursuant to Schedule Six of the AIM Rules for Companies regarding
its existing block admission arrangements:

 

 Name of applicant:                                                                     Scancell Holdings plc
 Number and class of securities originally admitted:                                    2,880,000 ordinary shares of £0.001 each
 Date of admission:                                                                     17 April 2023
 Period of return:                                         From:                        17 April 2023   To:             16 October 2023
 Balance of unallotted securities under scheme(s) from previous return:                 0
 Plus: The amount by which the block scheme(s) has been increased since the             0
 date of the last return (if any increase has been applied for):

 Less: Number of securities issued/allotted under scheme(s) during period (see          1,260,000
 LR3.5.7G):

 Equals: Balance under scheme(s) not yet issued/allotted at end of period:              1,620,000
 Total number of securities in issue at the end of the period                           819,663,561

 

 For further information, please contact:
 Scancell Holdings plc                                                        +44 (0) 20 3709 5700
 Dr Jean-Michel Cosséry, Non-Executive Chairman
 Professor Lindy Durrant, CEO

 Stifel Nicolaus Europe Limited (Nominated Adviser and Joint Broker)          +44 (0) 20 7710 7600
 Nicholas Moore/Samira Essebiyea/William Palmer-Brown (Healthcare Investment
 Banking)
 Nick Adams/Nick Harland (Corporate Broking)

 Panmure Gordon (UK) Limited (Joint Broker)                                   +44 (0) 20 7886 2500
 Freddy Crossley/Emma Earl (Corporate Finance)
 Rupert Dearden (Corporate Broking)

 ICR Consilium                                                                Tel.: +44 (0) 20 3709 5700
 Mary-Jane Elliott/Matthew Neal/Chris Welsh                                   scancell@consilium-comms.com (mailto:scancell@consilium-comms.com)

About Scancell

Scancell is a clinical stage biopharmaceutical company that is leveraging its
proprietary research, built up over many years of studying the human adaptive
immune system, to generate novel medicines to treat significant unmet needs in
cancer and infectious disease. The Company is building a pipeline of
innovative products by utilising its four technology platforms: Moditope(®)
and ImmunoBody(®) for vaccines and GlyMab(®) and AvidiMab(®) for
antibodies.

 

Adaptive immune responses include antibodies and T cells (CD4 and CD8), both
of which can recognise damaged or infected cells. In order to destroy such
cancerous or infected cells, Scancell uses either vaccines to induce immune
responses or monoclonal antibodies (mAbs) to redirect immune cells or drugs.
The Company's unique approach is that its innovative products target
modifications of proteins and lipids. For the vaccines (Moditope(®) and
ImmunoBody(®)) this includes citrullination and homocitrullination of
proteins, whereas its mAb portfolio targets glycans or sugars that are added
onto proteins and / or lipids (GlyMab(®)) or enhances the potency of
antibodies and their ability to directly kill tumour cells (AvidiMab(®)).

 

For further information about Scancell, please visit:
https://www.scancell.co.uk/ (https://www.scancell.co.uk/)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BLRBRBDGXDBDGXL